Suppr超能文献

[一例对替吉奥/多西他赛二线化疗有反应的复发性食管癌病例]

[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].

作者信息

Sugiyama Yoichi, Morifuji Masahiko, Murakami Yoshiaki, Uemura Kenichiro, Hayashidani Yasuo, Sudo Atsushi, Hashimoto Yasushi, Sueda Taijiro

机构信息

Dept. of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences, Hiroshima University.

出版信息

Gan To Kagaku Ryoho. 2006 Jun;33(6):795-8.

Abstract

A 70-year-old man suffering from advanced esophageal cancer (Stage II) underwent subtotal esophagectomy in December 2000. He then had postoperative chemotherapy, called low-dose FP, and was followed in an ambulatory setting. In December 2003, he was diagnosed as a recurrence of esophageal cancer with multiple liver metastases and upper mediastinum lymph node, so he was treated by combined chemotherapy consisting of TS-1 and docetaxel as a second-line chemotherapy. After 3 courses of this therapy, CT scan showed that the size of liver and lymph node metastases was reduced and the effect of this therapy was PR. PR continued for about 6 months. This chemotherapy made it possible to treat liver and lymph node metastasis in an ambulatory setting. It is conceivable that this combination chemotherapy might be a promising regimen for a short period.

摘要

一名70岁患有晚期食管癌(II期)的男性于2000年12月接受了食管次全切除术。随后他接受了名为低剂量FP的术后化疗,并在门诊接受随访。2003年12月,他被诊断为食管癌复发,伴有多处肝转移和上纵隔淋巴结转移,因此作为二线化疗接受了由替吉奥(TS-1)和多西他赛组成的联合化疗。经过3个疗程的这种治疗后,CT扫描显示肝和淋巴结转移灶的大小减小,该治疗效果为部分缓解(PR)。PR持续了约6个月。这种化疗使得在门诊环境中治疗肝和淋巴结转移成为可能。可以想象,这种联合化疗可能是短期内一种有前景的治疗方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验